ClinicalTrials.gg
Status unknownNCT05205915Updated Oct 5, 2022

Home-based Transcranial Direct Current Stimulation (tDCS) for Major Depressive Disorders (MDD)

An interventional study of tDCS intervention applied by Starstim device in Major Depressive Disorder, sponsored by Neuroelectrics Corporation. Status unknown at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-05.

Sponsored by Neuroelectrics Corporation · Not applicable, Interventional, and Device feasibility

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
912th of 1,323
34 · median 70
Started
2022
with 51 others
No phase
472 of 1,500
94 open now
Registered
1,160th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 912th largest by enrollment of the 1,323 interventional ones that give a count, is one of 52 that started in 2022, is one of 472 with no phase, and was the 1,160th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

211 more — sign in →

All 216 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This is an open label pilot feasibility telemedicine study. This pilot will involve a total of 37 at-home stimulation sessions (30-minutes each) of multichannel excitatory tDCS targeting the left dorsolateral prefrontal cortex (DLPFC) administered over 8 weeks, with a follow-up period of 4 weeks following the final stimulation session.

Read the detailed description

This is an open label pilot feasibility telemedicine study. This pilot will involve a total of 37 at-home stimulation sessions (30-minutes each) of multichannel excitatory tDCS targeting the left dorsolateral prefrontal cortex (DLPFC) administered over 8 weeks, with a follow-up period of 4 weeks following the final stimulation session.

The main objective of the study is to assess the feasibility and safety of home-based tDCS for patients with MDD.

The treatment course will consist of an acute phase of 28 tDCS sessions, conducted daily (7 days per week) over 4 weeks.

Thereafter, participants will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:

  1. Three tDCS sessions applied once every other day.
  2. Three tDCS sessions applied once every third day.
  3. Three tDCS sessions applied once every fourth day.
03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Major Depressive Disorder
  2. Age >=18
  3. Currently experiencing a major depressive episode of at least four weeks' duration
  4. MADRS score at least 20 at trial entry.
  5. Taking at least one approved antidepressant medication (except bupropion).
  6. Has a healthcare provider, and a companion who can help administer study treatments; and be able to connect frequently with study staff
  7. Access to wireless internet (wifi) connection

Exclusion criteria

Exclusion Criteria:

  1. Any psychotic disorder.
  2. Concurrent benzodiazepine medication.
  3. High suicide risk
  4. History of significant neurological disorder.
  5. Skin lesions on the scalp at the proposed electrode sites.
  6. Pregnancy.
  7. Any antidepressant medications will be permitted (except bupropion) provided the medication dose has been unchanged for 4 weeks prior to trial entry.
  8. Any cranial metal implants (excluding ≤1 mm thick epicranial titanium skull plates and dental fillings) or
  9. Medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant, vagus nerve stimulator);
  10. Previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm.
  11. Substance use disorder (including alcohol) within the past year.
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Single arm

    All patients will receive active treatment which consists of stimulation (tDCS) applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents).

    Device: tDCS intervention applied by Starstim device

Interventions

  • DevicetDCS intervention applied by Starstim device

    Stimulation will be applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents). The montage has been designed to optimize anodal stimulation in the desired target area while avoiding stimulation off target.

    Also known as: Starstim

06

What researchers measure

Primary outcomes

  1. Percentage of incomplete and missed sessions (%)

    Feasibility will be evaluated using home-based data as recorded in the Neuroelectrics portal. Range \[0,100\]. Higher is worse

    Time frame: From baseline to 4-week follow up across study subjects

  2. Incidence of Serious Adverse Events (SAE)

    Safety will be assessed by number and type of side effects

    Time frame: From baseline to 4-week follow up across study subjects

  3. Median percentage change in Montgomery-Asberg Depression Mood Rating Scale (MADRS) scores

    The primary efficacy measure for this study will be the median percent change from baseline to the end of the 4-week post-treatment follow-up period in the observer-rated Montgomery-Asberg Depression Mood Rating Scale (MADRS) (Montgomery and Asberg, 1979). Range \[0,100\]. Higher is worse

    Time frame: From baseline to 4-week follow up across study subjects

Secondary outcomes

  1. Response rate

    Response rate is the secondary efficacy endpoint and will be calculated for the study subjects, where clinical response is defined as ≥ 50% improvement in Montgomery-Asberg Depression Mood Rating Scale (MADRS) score. Higher is better

    Time frame: From baseline to the 4-week follow-up

  2. Change in the Quick Inventory of Depressive Symptomatology (QIDS-SR) score

    Range \[0,27\]. Higher is worse

    Time frame: Change from baseline to 4-week follow-up in the participant-rated Quick Inventory of Depressive Symptomatology (QIDS-SR)

  3. Change in the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) score

    Range \[14,70\]. Higher is better

    Time frame: Change from baseline to 4-week follow-up in the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF)

  4. Median percentage change in Montgomery-Asberg Depression Mood Rating Scale (MADRS) scores

    Time frame: From baseline to the end of week 4 of treatment, and to the end of week 8 of treatment.

07

Study locations

4 sites
  • Healthcare Innovations Institute, LLC
    Coral Springs, Florida 33067, United States
  • Oceane7 Medical & Research Center, Inc.
    Miami, Florida 33144, United States
  • Renew Health Clinical Research, LLC
    Snellville, Georgia 30078, United States
  • Conrad Clinical Research
    Edmond, Oklahoma 73013, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2022, 10 months after the start.

Of 40 industry-sponsored interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 10 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Jan 25, 2022
StartActual
Feb 2, 2022
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2022
Last update
Oct 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05205915
Lead sponsor
Neuroelectrics Corporation
Responsible party
Sponsor
First posted
Jan 25, 2022
Start date
Feb 2, 2022
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Oct 5, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion